



Sunday, 11.9.2011

8.00-10.00 Main Hall (Aula Duza)

Oral presentations 1: Topic Highlights (OP1-OP6)

Chairs: Peter Laurberg (Aalborg, Denmark); Barbara Jarzab (Gliwice, Poland)

8.00-8.20

OP01 E7080 IN ADVANCED RADIOIODINE (RAI)-REFRACTORY DIFFERENTIATED THYROID CANCER (DTC); RESULTS OF A MULTI-CENTER PHASE II TRIAL

Sherman SJ¹, Jarzab B², Cabanillas ME¹, Licitra L³, Pacini F⁴, Martins RG⁵, Robinson B⁶, Ball DW⁷, McCaffrey JC⁸, Shah MH⁹, Bodenner DL¹⁰, Allison R¹¹, Newbold K¹², Elisei R¹³, Gold A¹⁴, Andresen C¹⁴, O'Brien JP¹⁴, Schlumberger M¹⁵

¹The University of Texas MD Anderson Cancer Center, Houston, United States, ²Centrum Onkologii Instytut of Gliwice, Gliwice, Poland, ³Istituto Nazionale dei Tumori, Milano, Italy, ⁴Azienda Ospedaliera Universitaria Senese, Siena, Italy, ⁵Seattle Cancer Care Alliance, Seattle, United States, ⁶Royal North Shore Hospital, St. Leonards, Australia, ⁷John Hopkins Medical Institutes, Baltimore, United States, ⁸H. Lee Moffit Cancer Center, Tampa, United States, ⁹Ohio State University School of Medicine, Columbus, United States, ¹⁰University of Arkansas, Little Rock, United States, ¹¹The Royal Brisbane and Women's Hospital, Herston, Australia, ¹²Royal Marsden Hospital, Sutton, United Kingdom, ¹³Azienda Ospedaliera Universitaria Pisana, Pisa, Italy, ¹⁴Eisai Inc., Woodcliff Lake, United States, ¹⁵Institut Gustave-Roussy, Villejuif, France

8.20-8.40

OP02 THE CLINICAL PI3K INHIBITOR GDC-0941 RADIO-SENSITISES THYROID CARCINOMA CELLS BY INHIBITING BOTH THE PI3K AND HIF-1 SIGNALLING PATHWAYS

Burrows N¹, Williams J¹, Babur M¹, Resch J², Williams K¹, Brabant G²

¹University of Manchester, Hypoxia and Therapeutics Group, School of Pharmacy, Manchester, United Kingdom, ²University of Lübeck, Clinical and Experimental Endocrinology, Lübeck, Germany

8.40-9.00

OP03 EFFECTS OF CHRONIC 3-IODOTHYRONAMINE ADMINISTRATION ON LIPID METABOLISM IN RODENTS

Chiellini G¹, Assadi-Porter FM², Haviland J², Butz D², Frascarelli S¹, Pellegrini S³, Scanlan TS⁴, Zucchi R¹

¹University of Pisa, Dip. di Scienze dell'Uomo e dell'Ambiente, Pisa, Italy, ²University of Wisconsin, Madison, United States, ³University of Pisa, Dip. di Patologia Sperimentale, Pisa, Italy, ⁴Oregon Health & Science University, Portland, United States

9.00-9.20

OP04 NEUROENDOCRINE C CELLS OF THE MOUSE THYROID ORIGINATE FROM FOREGUT PROGENITORS IN THE ANTERIOR ENDODERM

Nilsson M¹, Andersson L², Westerlund J², Carlsson T¹, Parrillo L³, Zoppoli P³, Lania G⁴, Baldini A⁴, Fagman H¹

¹Cancer Center Sahlgrenska, Gothenburg University, Institute of Biomedicine, Göteborg, Sweden, ²Gothenburg University, Institute of Biomedicine, Göteborg, Sweden, ³IRGS, Biogem s.c.ar.l, Ariano Irpino, Italy, ⁴Telethon Institute of Genetics and Medicine, Naples, Italy

9.20-9.40

OP05 A MULTICENTER RANDOMIZED PROSPECTIVE TRIAL OF PERCUTANEOUS LASER ABLATION VERSUS FOLLOW-UP FOR THE TREATMENT OF COLD THYROID NODULES. SIX-MONTH RESULTS

Papini E¹, Valcavi R², Rago T³, Vitti P³, Gambelunghe G⁴, De Feo P⁴, Bizzarri G¹, Pacella C²

¹Regina Apostolorum Hospital, Department of Endocrinology, Albano Laziale, Italy, ²Thyroid Disease Center, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy, ³Department of Endocrinology, University of Pisa, Pisa, Italy, ⁴Department of Internal Medicine and Endocrine and Metabolic Sciences, Perugia, Italy

9.40-10.00

OP06 A NOVEL CHIMERIC TSHR BIOASSAY DETECTS BOTH THYROID BLOCKING AND STIMULATING IMMUNOGLOBULINS

Olivo PD¹, Kim J¹, Larrimer A¹, Klasen R¹, Kanitz M², Li Y¹, Kahaly GJ²

¹Diagnostic Hybrids, Inc. (A Quidel Company), Athens, United States, ²Gutenberg University Medical Center, Thyroid Research Laboratory, Mainz, Germany

10.00-10.10 Main Hall (Aula Duza)

Lissitzky Career Award

(The 2011 award is sponsored exclusively by Diagnostic Hybrids, Ohio, USA)

Chairs: Peter Laurberg (Aalborg, Denmark); Luigi Bartalena (Varese, Italy)

10.10-10.30 Coffee Break

10.30-12.00 Minor Hall

Symposium 1 Basic: Local control of thyroid hormone action

Chair: Agnieszka Piekuelko-Witkowska (Warsaw, Poland); Marek Niedziela (Poznan, Poland)

Control of deiodinase expression in malignancy

Domenico Salvatore (Naples, Italy)

The essential role of D2 in bone

Duncan Bassett (London, UK)

Understanding the HPT axis in MCT8 deficiency

Heike Heuer (Jena, Germany)

10.30-12.00 Main Hall (Aula Duza)

Symposium 2 Clinical: Pregnancy and Graves' disease

Chair: Jacques Orgiazzi (Lyon, France); Gerasimos Krassas (Thessaloniki, Greece)

Preconception counseling in Graves' disease

John Lazarus (Cardiff, UK)

Side effects of antithyroid drugs

Bijay Vaidya (Exeter, UK)

Management of Graves' hyperthyroidism in pregnancy

Luca Chiovato (Pavia, Italy)

12.00-13.00 Poster Exhibition Area

Lunch and Poster Discussions 1 Poster Sessions PO1-P10

Posters P01-P115

Thyroid Cancer (clinical) 1: Posters PO1-P10 / *Chair: Ulla Feldt-Rasmussen (Copenhagen, Denmark)*

Thyroid Cancer (clinical) 2: Posters P11-P19 / *Chair: Markus Luster (Ulm, Germany)*

Thyroid Cancer (clinical) 3: Posters P20-P29 / *Chair: Laura Fugazzola (Milan, Italy)*

Thyroid Cancer (basic/translational) 1: Posters P30-P39 / *Chair: Clara Alvarez (Santiago de Compostela, Spain)*

Graves' Orbitopathy 1: Posters P40-P53 / *Chair: Valentin Fadeyev (Moscow, Russia)*

Graves' Hyperthyroidism 1: Posters P54-P65 / *Chair: Paolo Vitti (Pisa, Italy)*

Thyroid Hormone & Metabolism 1: Posters P66-P73 / *Chair: István Szabolcs (Budapest, Hungary)*

Hypothyroidism 1: Posters P74-P87 / *Chair: Annick van den Bruel (Bruges, Belgium)*

Cytology: Posters P88-P101 / *Chair: Teresa Rago (Pisa, Italy)*

Pregnancy: Posters P102-P115 / *Chair: Milos Zarkovic (Belgrade, Serbia)*

13.00-14.00 Main Hall (Aula Duza)

Lunch Symposium AstraZeneca

Sharing Real-Life Experiences in Medullary Thyroid Cancer

Welcome

Barbara Jarzab (Gliwice, Poland)

Introduction

Richard Kloos (Columbus, USA)

Case studies

Expert panel discussion with audience interaction

Rossella Elisei (Italy) and Lori Wirth (USA)

Summary and close

Richard Kloos

14.00-14.45 Main Hall (Aula Duza)

ETA Harington-de Visscher Prize Lecture

Chair: Peter Laurberg (Denmark) and Luigi Bartalena (Italy)

Francesca Carlomagno (Naples, Italy)

Thyroid cancer: role of RET and beyond

14.45-15.00 Coffee Break

15.00-15.45

Meet the Expert (parallel sessions)

MTE 1 MTE Hall Non-mammalian models to study thyroid development

Luca Persani (Milan, Italy)

MTE 2 Senate Hall Thyroid hormone resistance and metabolism

Krishna Chatterjee (Cambridge, UK)

MTE 3 Lecture Hall The role of thyroid hormone in heart failure

Warner Simonides (Amsterdam, The Netherlands)

MTE 4 Minor Hall Treatment of difficult cases of thyroid carcinoma

Martin Schlumberger (Paris, France)

16.00-18.00 Minor Hall

Oral presentations 2: Thyroid Cancer translational (OP7-OP14)

Chair: Furio Pacini (Siena, Italy); Malgorzata Karbownik-Lewinska (Lodz, Poland)

16.00-16.15

OP07 EPIDERMAL GROWTH FACTOR RECEPTOR-TARGETED NON-VIRAL DELIVERY OF THE SODIUM IODIDE SYMPORTER (NIS) GENE IN RADIOIODINE-REFRACTORY DIFFERENTIATED AND ANAPLASTIC THYROID CANCER

Dolp PA¹, Klutz K¹, Wunderlich N¹, Grünwald GK¹, Willhauck MJ¹, Knoop K¹, Vetter A², Rödl W², Wagner E², Göke B¹, Ogris M², Spitzweg C¹

¹Ludwig-Maximilians-University, Department of Internal Medicine II, Munich, Germany, ²Ludwig-Maximilians-University, Department of Pharmacy, Center of Drug Research, Pharmaceutical Biotechnology, Munich, Germany

16.15-16.30

OP08 OUTCOME OF A CONSERVATIVE MANAGEMENT POLICY FOR FOLLICULAR THYROID CANCER - A PROSPECTIVE LONGITUDINAL COHORT STUDY

Mackay I^{1,2}, Craig W^{1,2}, Smart L^{2,3}, Krukowski ZH^{1,2}

¹Aberdeen Royal Infirmary, Department of General Surgery, Aberdeen, United Kingdom, ²University of Aberdeen, Aberdeen, United Kingdom, ³Department of Pathology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom

16.30-16.45

OP09 THE IODINE DEFICIENCY-INDUCED ANGIOGENIC PATHWAY IN THYROID CANCER CELLS OCCURS VIA A VEGF-HIF SIGNALLING PATHWAY THAT, IN CONTRAST WITH NON MALIGNANT CELLS, IS INDEPENDENT ON REACTIVE OXYGEN SPECIES

Gerard A-C¹, Humblet K¹, Derradji H², Baatout S², de ville de Goyet C¹, Sonveaux P³, Deneff J-F¹, Colin JM¹

¹Universite catholique de Louvain, IREC, Pôle de Morphologie, Bruxelles, Belgium, ²Belgian Nuclear Centre, SCK-CEN, radiobiology unit, Mol, Belgium, ³Universite catholique de Louvain, IREC, Pôle de Pharmacologie Thérapeutique, Bruxelles, Belgium

16.45-17.00

OP10 FAMILIAL PAPILLARY THYROID CANCER PATIENTS DISPLAY AN ELEVATED CHROMOSOME FRAGILITY CHARACTERIZED BY TELOMERIC ASSOCIATION AND TELOMERE LOSS

Cantara S¹, Pisu M¹, Capuano S¹, Capezzone M¹, Frau D², Caria P², Marchisotta S¹, Busonero G¹, Formichi C¹, Vanni R², Pacini F¹

¹University of Siena, Department of Internal Medicine, Endocrinology and Metabolism and Biochemistry, Section of Endocrinology and Metabolism, Siena, Italy, ²University of Cagliari, Department of Biomedical Technologies and Sciences, Monserrato, Italy

17.00-17.15

OP11 HUMAN LEUKOCYTE ANTIGEN-G POLYMORPHISM: A POTENTIAL MARKER OF HISTOLOGICAL AGGRESSIVENESS IN PAPILLARY THYROID CANCER

Dardano A¹, Rizzo R², Polini A¹, Stignani M², Tognini S¹, Pasqualetti G¹, Colato C³, Ferdeghini M³, Baricordi O², Monzani F¹

¹University of Pisa, Department of Internal Medicine, Pisa, Italy, ²University of Ferrara, Department of Experimental and Diagnostic Medicine, Ferrara, Italy, ³University of Verona, Department of Morphological and Biomedical Sciences, Verona, Italy

17.15-17.30

OP12 HIGH-RESOLUTION-MELTING-CURVE ANALYSIS (HRM) FOR BRAF^{V600E} AND NRAS MUTATION SCREENING IN ROUTINE AIR DRIED THYROID FNA SMEARS IS MORE RELIABLE AND MORE SENSITIVE THAN FLUORESCENCE RESONANCE ENERGY TRANSFER (FRET) PROBES ANALYSIS

Rehfeld C¹, Krogdahl A², Ferraz C¹, Precht Jensen EM², Bösenberg E¹, Hegedüs L³, Paschke R¹, Eszlinger M¹

¹University of Leipzig, Division of Endocrinology and Nephrology, Leipzig, Germany, ²Odense University Hospital, Department of Pathology, Odense, Denmark, ³Odense University Hospital, Department of Endocrinology and Metabolism, Odense, Denmark

17.30-17.45

OP13 MICRORNA EXPRESSION IN EXPERIMENTAL *IN VITRO* THYROID TUMORS MODELS

Floor S¹, Pita JM^{1,2}, Saiselet M¹, Le Pennec S¹, Libert F¹, van Staveren WCG¹, Maenhaut C¹

¹ULB, IRIBHM, Anderlecht, Belgium, ²de Patobiologia Molecular (CIPM), Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal

17.45-18.00

OP14 SERUM ANTI-THYROID ANTIBODIES (TAB): A POSSIBLE NEW POSITIVE PREDICTIVE PARAMETER IN HIGH AGGRESSIVE BREAST CANCER (BC)

Muller J¹, Fiore E¹, Belardi V¹, Sabatini S¹, Giustarini E¹, Vitti P¹, Giani C¹

¹University of Pisa, Endocrinology, Pisa, Italy

16.00-18.00 Main Hall (Aula Duza)

Oral presentations 3: Young Investigators Session (OP15-OP22)

Chair: Paul Banga (London, UK); Marek Ruchala (Poznan, Poland)

16.00-16.15

OP15 MIR-224 CONTRIBUTES TO TISSUE HYPOTHYROIDISM IN RENAL CANCER, TARGETING THE 3'UTR OF TYPE 1 5'-IODOTHYRONINE DEIODINASE

Boguslawska J¹, Piekielko-Witkowska A¹, Wojcicka A¹, Master A¹, Nauman A¹

¹The Medical Centre of Postgraduate Education, Department of Biochemistry and Molecular Biology, Warsaw, Poland

16.15-16.30

OP16 DEFICIENCY OF THE THYROID HORMONE TRANSPORTER MONOCARBOXYLATE TRANSPORTER 8 ALTERS THYROID MORPHOLOGY IN A PATIENT AND IN MICE

Wirth EK¹, Sheu S-Y², Chiu-Ugalde J¹, Sapin R³, Klein MO⁴, Mossbrugger I⁵, Quintanilla-Martinez L^{5,6}, Krude H⁷, Riebel T⁸, Rothe K⁹, Köhrle J¹, Schmid KW², Schweizer U¹, Grüters A⁷

¹Charité-Universitätsmedizin Berlin, Institut f. Experimentelle Endokrinologie, Berlin, Germany,

²Universität Duisburg-Essen, Institut für Pathologie und Neuropathologie, Essen, Germany,

³Université de Strasbourg, Centre National de la Recherche Scientifique, Strasbourg, France, ⁴Centre

Hospitalier et Universitaire de Nancy, Service D'Endocrinologie, Nancy, France, ⁵Helmholtz-Zentrum

München, German Mouse Clinic, München, Germany, ⁶Eberhard Karls Universität Tübingen, Institut

für Pathologie, Tübingen, Germany, ⁷Charité-Universitätsmedizin Berlin, Institut für Experimentelle

Pädiatrische Endokrinologie, Berlin, Germany, ⁸Charité-Universitätsmedizin Berlin, Klinik für

Strahlenheilkunde, Pädiatrische Radiologie, Berlin, Germany, ⁹Charité-Universitätsmedizin Berlin,

Klinik für Kinderchirurgie, Berlin, Germany

16.30-16.45

OP17 SOMATIC HYPERMUTATION OF THE IMMUNOGLOBULIN HEAVY CHAIN VARIABLE-REGION OF THYROID STIMULATING ANTIBODIES DETERMINES BINDING TO THE TSH-RECEPTOR

Hargreaves C¹, Dunn-Walters D², Banga JP¹

¹King's College London School of Medicine, Diabetes and Endocrinology, London, United Kingdom,

²King's College London School of Medicine, Immunobiology, London, United Kingdom

16.45-17.00

OP18 DETECTION OF PAX8/PPARG AND RET/PTC REARRANGEMENTS IN ROUTINE AIR DRIED FINE NEEDLE ASPIRATION (FNA) SMEARS

Ferraz C¹, Krogdahl A², Rehfeld C¹, Precht Jensen EM², Bösenberg E¹, Hegedüs L³, Paschke R¹, Eszlinger M¹

¹University of Leipzig, Division of Endocrinology and Nephrology, Leipzig, Germany, ²Odense

University Hospital, Department of Pathology, Odense, Denmark, ³Odense University Hospital,

Department of Endocrinology and Metabolism, Odense, Denmark

17.00-17.15

OP19 DUAL-OXIDASE 2 GENETIC MODIFICATIONS IN CHILDREN WITH HYPOTHYROIDISM: IDENTIFICATION AND FUNCTIONAL ANALYSIS OF VARIANTS AND MUTATIONS

Molinaro A¹, De Marco G¹, Montanelli L¹, Agretti P¹, Bagattini B¹, Dimida A¹, Ferrarini E¹, Niccolai F¹, Bottai S¹, Ceccarelli C¹, Brozzi F¹, Pinchera A¹, Vitti P¹, Tonacchera M¹

¹Università di Pisa, Endocrinology and Metabolism, Pisa, Italy

17.15-17.30

OP20 RELATIONS BETWEEN MATERNAL FIRST-TRIMESTER AND NEWBORN THYROID HORMONE SERUM LEVELS: RESULTS FROM A LARGE POPULATION-BASED COHORT STUDY

Medici M¹, de Rijke YB^{1,2}, Peeters RP¹, Visser W³, de Muinck Keizer-Schrama SMPF⁴, Hooijkaas H⁵, Tiemeier H^{6,7}, Bongers-Schokking JJ⁴, Visser TJ¹

¹Erasmus Medical Center, Endocrinology, Rotterdam, Netherlands, ²Erasmus Medical Center - Sophia Children's Hospital, Clinical Chemistry, Rotterdam, Netherlands, ³Erasmus Medical Center - Sophia Children's Hospital, Obstetrics and Gynecology, Rotterdam, Netherlands, ⁴Erasmus Medical Center - Sophia Children's Hospital, Endocrinology, Rotterdam, Netherlands, ⁵Erasmus Medical Center, Immunology, Rotterdam, Netherlands, ⁶Erasmus Medical Center, Epidemiology, Rotterdam, Netherlands, ⁷Erasmus Medical Center - Sophia Children's Hospital, Child and Adolescent Psychiatry, Rotterdam, Netherlands

17.30-17.45

OP21 IS COMPLETION THYROIDECTOMY FOLLOWING LOBECTOMY FOR LOW RISK THYROID CANCER MANDATORY?

Craig W^{1,2}, Krukowski ZH^{1,2}

¹Aberdeen Royal Infirmary, Department of General Surgery, Aberdeen, United Kingdom, ²University of Aberdeen, Aberdeen, United Kingdom

17.45-18.00

OP22 SELECTIVE VENOUS CATHETERIZATION IN LOCALIZING OCCULT PERSISTENT MEDULLARY THYROID CARCINOMA

Hajje G¹, Borget I², Baudin E¹, Hartl D³, Deschamps F⁴, Schlumberger M¹, De Baere T⁴, Leboulleux S¹

¹Institut Gustave Roussy, Endocrinology-Oncology Department, Villejuif, France, ²Institut Gustave Roussy, Department of Statistics, Villejuif, France, ³Institut Gustave Roussy, Ear Nose Throat Department, Villejuif, France, ⁴Institut Gustave Roussy, Interventional Radiology Department, Villejuif, France

18.00-18.30 Main Hall (Aula Duza)

Special Report: The Fukushima Accident

Chair: Aldo Pinchera (Pisa, Italy); Leszek Krolicki (Warsaw, Poland)

Shigenobu Nagataki (Tokyo, Japan)

18.30-20.00 Main Hall (Aula Duza)

ETA 2011 Merck Serono Satellite Symposium

Subclinical hypothyroidism through all ages

Chairperson: **George J. Kahaly (Mainz, Germany)**

Welcome Introduction

George J. Kahaly

Management of subclinical hypothyroidism during pregnancy and the postpartum

Kris Poppe (Brussels, Belgium)

Increased morbidity and cardiovascular risk in subclinical hypothyroidism

Simon H. Pearce (Newcastle upon Tyne, UK)

Personalized rationale for thyroid hormone replacement

Antonio C. Bianco (Miami, USA)

Symposium participants are cordially invited to a cocktail reception immediately following the event.

Monday, 12.9.2011

7.00-8.00 Main Hall (Aula Duza)

Early Riser Symposium Genzyme

Ablation at the cutting edge; defining new treatment paradigms for the 21st Century

Chairman: Martin Schlumberger (Paris, France)

Introduction: what is the rationale for ablation in thyroid cancer management?

Martin Schlumberger (Paris, France)

The UK HiLo study: final efficacy results

Ujjal Mallick (Newcastle, UK)

The French ESTIMABL ablation study. What are the implications for practice?

Isabelle Borget (Paris, France)

Round table discussion and questions

8.00-10.00 Main Hall (Aula Duza)

Oral presentations 4: Thyroid Autoimmunity (OP23-OP30)

Chair: Jadwiga Furmaniak (Cardiff, UK); Wojciech Zgliczynski (Poland)

8.00-8.15

OP23 DIFFERENCES IN THE WAY STIMULATING AND BLOCKING MONOCLONAL AUTOANTIBODIES INTERACT WITH THE TSHR

Núñez Miguel R¹, Sanders J¹, Young S¹, Sanders P¹, Kabelis K¹, Clark J¹, Wilmot J¹, Evans M¹, Hu X¹, Roberts E¹, Furmaniak J¹, Rees Smith B¹

¹FIRS Laboratories, RSR Ltd, Cardiff, United Kingdom

8.15-8.30

OP24 CAVEOLINE-1 EXPRESSION DIFFERS ACCORDING TO THE TYPE OF IMMUNE REACTION (TH1/TH2) INVOLVED IN THYROID AUTOIMMUNE DISORDERS

Marique L¹, Van Regemorter V¹, Craps J¹, Senou M¹, Gérard A-C¹, Many M-C¹

¹UCL, MORF, Brussels, Belgium

8.30-8.45

P25 NEWLY IDENTIFIED IMMUNOSUPPRESSIVE NATURAL KILLER (NK) CELLS SUPPRESS ANTIGEN-SPECIFIC CD8+ T CELLS IN THREE MOUSE MODELS FOR AUTOIMMUNITY

Ehlers M¹, Papewalis C¹, Thiel A¹, Jacobs B², Ullrich E², Willenberg HS¹, Schinner S¹, Scherbaum WA¹, Schott M¹

¹University Hospital Duesseldorf, Endocrine Unit, Duesseldorf, Germany, ²University of Erlangen-Nürnberg, Erlangen, Germany

8.45-9.00

OP26 INVOLVEMENT OF STRESS IN THE PATHOGENESIS OF AUTOIMMUNE THYROID DISEASE: A PROSPECTIVE STUDY

Effraimidis G¹, Tijssen JGP², Wiersinga WM¹

¹Academic Medical Centre, University of Amsterdam, Department of Endocrinology and Metabolism, Amsterdam, Netherlands, ²Academic Medical Centre, University of Amsterdam, Department of Cardiology, Amsterdam, Netherlands

9.00-9.15

OP27 ROLE OF THE PRO-PEPTIDE SEQUENCE IN THYROID PEROXIDASE FUNCTION AND MATURATION

Godlewska M¹, Banga JP², Sutton BJ³, Krasuska W¹, Weetman AP⁴, Kemp EH⁴, Góra M⁵

¹Medical Centre of Postgraduate Education, Department of Biochemistry and Molecular Biology, Warsaw, Poland, ²King's College London School of Medicine, Division of Diabetes and Nutrition Sciences, London, United Kingdom, ³King's College London School of Medicine, Randall Division of Cell & Molecular Biophysics, London, United Kingdom, ⁴University of Sheffield, Department of Human Metabolism, Sheffield, United Kingdom, ⁵Institute of Biochemistry and Biophysics PAS, Department of Genetics, Warsaw, Poland

9.15-9.30

OP28 ALCOHOL CONSUMPTION IS PROTECTIVE FOR DEVELOPMENT OF AUTOIMMUNE HYPOTHYROIDISM - A POPULATION-BASED STUDY

*Carlé A¹, Pedersen IB¹, Knudsen N², Perrild H², Ovesen L³, Rasmussen LB⁴, Jørgensen T⁵, Laurberg P¹, *The Danish Investigation of Iodine Intake and Thyroid Diseases (DanThyr)**

¹Aalborg Hospital, Aarhus University Hospital, Department of Endocrinology & Medicine, Aalborg, Denmark, ²Bispebjerg Hospital, Endocrine Unit, Medical Clinic I, Copenhagen, Denmark, ³Slagelse Hospital, Department of Internal Medicine, Slagelse, Denmark, ⁴National Food Institute, Technical University of Denmark, Department of Nutrition, Copenhagen, Denmark, ⁵Copenhagen County, Research Centre for Disease Prevention and Health, Copenhagen, Denmark

9.30-9.45

OP29 THYROID AUTOIMMUNITY IN MALIGNANT AND BENIGN BREAST DISEASE BEFORE SURGERY

Belardi V¹, Giustarini E¹, Fiore E¹, Muller I¹, Sabatini S¹, Pinchera A¹, Giani C¹

¹Università di Pisa, Endocrinology, Pisa, Italy

9.45-10.00

OP30 THYROID AUTOIMMUNITY AND HASHIMOTO'S THYROIDITIS AFTER UNIVERSAL IODINE PROPHYLAXIS: THE 2010 PESCOGAGANO SURVEY

Provenzale MA¹, Fiore E¹, Frigeri M¹, Puleo L¹, Antonangeli L¹, Rago T¹, Grasso L¹, Pinchera A¹, Aghini-Lombardi F¹, Vitti P¹

¹Department of Endocrinology, University of Pisa, Pisa, Italy

8.00-10.00 Minor Hall

Oral presentations 5: Thyroid Hormone 1 (OP31-OP38)

Chair: Jacques Dumont (Brussels, Belgium); Marek Bolanowski (Wroclaw, Poland)

8.00-8.15

OP31 EFFECT OF LACKING GPB5 ON DEIODINASE EXPRESSION IN PERIPHERAL TISSUES THAT EXPRESS THE THYROTROPIN RECEPTOR

Boelen A¹, van Zeijl CJ¹, Kwakkel J¹, van Beeren HC¹, Surovtseva OV¹, Wiersinga WM¹, Fliers E¹

¹Academic Medical Center, Endocrinology and Metabolism, Amsterdam, Netherlands

8.15-8.30

OP32 ANALYSIS OF MOUSE MUTANTS DEFICIENT IN THE THYROID HORMONE TRANSPORTER OATP1C1

Mayerl S¹, Visser TJ², Darras VM³, Heuer H¹

¹Leibniz Institute for Age Research/Fritz Lipmann Institute, Jena, Germany, ²Erasmus Medical Center, Rotterdam, Netherlands, ³Katholieke Universiteit, Leuven, Belgium

8.30-8.45

OP33 CARDIAC INDUCTION OF THE THYROID-HORMONE DEGRADING ENZYME DEIODINASE TYPE III IN HUMAN ISCHEMIC HEART DISEASE

Muller A¹, Pol C¹, Janssen R¹, Zuidwijk M¹, Joseph S², Cameron D², dos Remedios C², Visser T³, Paulus W¹, Simonides W¹

¹VU University Medical Center, Amsterdam, Netherlands, ²The University of Sydney, Sydney, Australia, ³Erasmus University Medical Center, Rotterdam, Netherlands

8.45-9.00

OP34 DIFFERENTIAL EXPRESSION PATTERN OF THYROID HORMONE TRANSPORTERS IN THE MOUSE CNS

Hahn C¹, Müller J¹, Romanova D¹, Mayerl S¹, Friesema EC², Visser TJ², Heuer H¹

¹Leibniz Institute for Age Research/Fritz Lipmann Institute, Jena, Germany, ²Erasmus Medical Center, Rotterdam, Netherlands

9.00-9.15

OP35 LIVER THYROID HORMONE CONCENTRATIONS IN RATS ON AMIODARONE OR DRONEDARONE TREATMENT CORRELATE WITH LIVER DEIODINASE ACTIVITIES AND ARE INDEPENDENT OF LIVER THYROID HORMONE TRANSPORTERS

Beeren HCV¹, Ackermans MT², Wiersinga WM², Fliers E², Boelen A²

¹Academic Medical Centre, University of Amsterdam, Endocrinology, Amsterdam, Netherlands,

²Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands

9.15-9.30

OP36 SELENIUM AND THYROID HORMONES IN POSTMENOPAUSAL HEALTHY WOMEN

Hoeg A¹, Gogakos A², Murphy E², Mueller S¹, Reid D³, Gluer CC⁴, Felsenberg D⁵, Roux C⁶, Eastell R⁷, Köhrle J¹, Schomburg L¹, Williams G²

¹Charité Universitätsmedizin Berlin, Institute for Experimental Endocrinology, Berlin, Germany,

²Imperial College London, Department of Medicine and MRC Clinical Sciences Centre, London, United Kingdom,

³University of Aberdeen, School of Medicine and Dentistry, Aberdeen, United Kingdom,

⁴Universitätsklinikum Schleswig-Holstein, Kiel, Germany, ⁵Free University of Berlin, Berlin, Germany,

⁶Paris Descartes University, Paris, France, ⁷University of Sheffield, Sheffield, United Kingdom

9.30-9.45

OP37 REGULATION OF BRAIN TH SIGNALLING DURING THE PERINATAL PERIOD IN EUTHYROID AND HYPOTHYROID PUPS

Morvan-Dubois G¹, Ghaddab R¹, Seugnet I¹, Veillard T¹, Perret-Jeanneret M¹, Clerget-Froidevaux M-S¹, Demeneix B¹

¹UMR7221 CNRS/MNHN, Paris cedex, France

9.45-10.00

OP38 EFFECTS OF AMIODARONE (AMIO) ON THYROID HORMONE (TH) TRANSPORT AND METABOLISM

van Heerebeek RE¹, Mandu N¹, Friesema EC¹, Chong L-F¹, Visser TJ¹

¹Erasmus MC, Internal Medicine, Thyroid Lab, Rotterdam, Netherlands

10.00-10.30 Coffee Break

10.30-12.00 Minor Hall

Symposium 3 Basic: Profiling the thyroid

Chair: Mariastella Zannini (Naples, Italy); Andrzej Lewinski (Lodz, Poland)

Finding thyroid cancer markers by omics

Dagmar Führer (Essen, Germany)

Profiling thyroid embryology

Roberto Di Lauro (Naples, Italy)

Genome-wide analysis of thyroid signaling

Pilar Santisteban (Madrid, Spain)

10.30-12.00 Main Hall (Aula Duza)

Symposium 4 Clinical: Where are the limits of overdiagnosis and overtreatment of thyroid disease?

Chair: Peter Laurberg (Aalborg, Denmark); Barbara Jarzab (Gliwice, Poland)

Thyroid nodules: indications to and extent of surgery

Henning Dralle (Halle, Germany)

Thyroid autoimmunity

Stefano Mariotti (Cagliari, Italy)

Subclinical functional abnormalities in the elderly

Simon Pearce (Newcastle, UK)

12.00-13.00 Poster Exhibition Area

Lunch and Poster Discussions 2 Poster Sessions P11-P19

Posters P116-P211

Thyroid Cancer (clinical) 4: Posters P116-P125 / *Chair: Chantal Daumerie (Brussels, Belgium)*

Thyroid Cancer (clinical) 5: Posters P126-P135 / *Chair: Valeriano Leite (Lisbon, Portugal)*

Thyroid Cancer (clinical) 6: Posters P136-P145 / *Chair: Bengt Hallengren (Malmö, Sweden)*

Thyroid Cancer (basic/translational) 2: Posters P146-P154 / *Chair: Rosa Marina Melillo (Naples, Italy)*

Graves' Hyperthyroidism 2: Posters P155-P165 / *Chair: Colin Dayan (Cardiff, UK)*

Thyroid Hormone & Metabolism 2: Posters P166-P172 / *Chair: Jean-Louis Wemeau (Lille, France)*

Goiter/Nodules 1: Posters P173-P185 / *Chair: Roland Gärtner (Munich, Germany)*

Imaging in Thyroidology: Posters P186-P201 / *Chair: Murat Erdogan (Ankara, Turkey)*

Trace elements and environment: Posters P202-P211 / *Chair: Nils Knudsen (Smorum, Denmark)*

13.00-14.00 Main Hall (Aula Duza)

IBSA Satellite Symposium

Levothyroxine malabsorption: experience with the softgel capsules

Chairmen: Aldo Pinchera (Pisa, Italy) and George J. Kahaly (Mainz, Germany)

Welcome and introduction

George J. Kahaly (Mainz, Germany)

The pharmacokinetics of levothyroxine softgel capsules

Murray P. Ducharme (Montreal, Canada)

Novel developments with softgel capsules

Salvatore Benvenga (Messina, Italy)

Individually tailored dose of thyroxine: a role for gastric acid secretion

Marco Centanni (Latina, Italy)

Round-table discussion

Moderation: Aldo Pinchera (Pisa, Italy)

End of session

13.00 - 14.00 Minor Hall

TFI-ETA Patient-Forum

Thyroid Federation International and European Thyroid Association invite all patients to the annual TFI-ETA Patient-Forum.

- 13.00 Opening by Yvonne Andersson, Sweden (President of TFI)
- 13.05 "Thyroid cancer, diagnostic, treatment and perspectives"
The latest developments on patient level on thyroid cancer
Martin Schlumberger (Paris, France)
- 13:25 "Psychological aspects of work with Thyroid Cancer Patients"
The psychological effects of thyroid cancer on patients and how to deal with them
Anna Syska-Bielak (Gliwice, Poland)
- 13:45 Questions by patients
- 13:55 Round up by Yvonne Andersson

During the lectures and the questions Polish doctors will be available for translations.

14.00-14.45 Main Hall (Aula Duza)

ETA Merck Serono Prize Lecture

Chair: Peter Laurberg (Denmark); Luigi Bartalena (Italy)

Autoimmunity in Graves' ophthalmopathy: a translational approach

Wilmar Wiersinga (Amsterdam, The Netherlands)

14.45-15.00 Coffee Break

15.00-15.45

Meet the Expert (parallel sessions)

- | | | |
|--------------|---------------------|---|
| MTE 5 | MTE Hall | Non-nuclear thyroid hormone actions
Lutz Schomburg (Berlin, Germany) |
| MTE 6 | Lecture Hall | Rare causes of altered thyroid function tests
Graham Williams (London, UK) |
| MTE 7 | Senate Hall | Thyroid hormones and obesity
Leonidas Duntas (Athens, Greece) |
| MTE 8 | Minor Hall | Guideline-oriented diagnosis and treatment of thyroid nodules
Ralf Paschke (Leipzig, Germany) |

16.30

Departure for Excursion to Wieliczka Salt Mine

Tuesday, 13.9.2011

8.00-10.00 Main Hall (Aula Duza)

Oral presentations 6: Graves' Disease (OP39-OP46)

Chair: Matthias Schott (Düsseldorf, Germany); Marcin Barczynski (Krakow, Poland)

8.00-8.15

OP39 A NOVEL MECHANISM INVOLVED IN THE PATHOGENESIS OF GRAVES OPHTHALMOPATHY (GO) - CLATHRIN IS A POSSIBLE TARGETING MOLECULE FOR INHIBITING LOCAL IMMUNE RESPONSE IN THE ORBIT

Meyer zu Hörste M^{1,2}, Ströher E¹, Schmitz-Spanke S³, Pink M³, Göthert J⁴, Fischer J⁵, Gulbins E², Eckstein A¹

¹University Hospital Essen, Department of Ophthalmology, Essen, Germany, ²University Hospital Essen, Department of Molecular Biology, Essen, Germany, ³University Hospital Essen, Department of Hygiene and Occupational Medicine, Essen, Germany, ⁴University Hospital Essen, Department of Hematology, Essen, Germany, ⁵University Hospital Essen, Department of Pharmacology, Essen, Germany

8.15-8.30

OP40 THE ECONOMIC BURDEN OF GRAVES' ORBITOPATHY

Ponto KA¹, Hommel G², Pitz S¹, Pfeiffer N¹, Kahaly GJ¹

¹University Medical Center, Ophthalmology, Mainz, Germany, ²University Medical Center, Medical Statistics, Mainz, Germany

8.30-8.45

OP41 SERUM BAFF CONCENTRATIONS IN PATIENTS WITH GRAVES' DISEASE (GD) AND ORBITOPATHY (GO) BEFORE AND AFTER IMMUNOSUPPRESSIVE TREATMENT

Vannucchi G¹, Covelli D¹, Currò N², Maffini A¹, Dazzi D³, Bonara P⁴, Pignataro L⁵, Beck-Peccoz P¹, Salvi M¹

¹Endocrine Unit, Fondazione Cà Granda IRCCS, Milan, Italy, ²Ophthalmology, Fondazione Cà Granda, IRCCS, Milan, Italy, ³Division of Internal Medicine, Fidenza, Italy, ⁴Internal Medicine, Fondazione Cà Granda IRCCS, Milan, Italy, ⁵Otolaryngology, Fondazione Cà Granda IRCCS, Milan, Italy

8.45-9.00

OP42 CIRCULATING CXCL10 AND CCL2 CHEMOKINES IN PATIENTS WITH GRAVES' OPHTHALMOPATHY WITH PREVALENT EXTRAOCULAR MUSCLE INVOLVEMENT: MODULATION BY CYTOKINES AND BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA AGONISTS IN PRIMARY MYOBLASTS

Ferrari SM¹, Fallahi P¹, Sellari Franceschini S², Ferrannini E¹, Minuto M³, Mancusi C¹, Ruffilli I¹, Antonelli A¹

¹University of Pisa, Department of Internal Medicine, Pisa, Italy, ²University of Pisa, Otorhinolaryngology Unit, Pisa, Italy, ³University of Pisa, Department of Surgery, Pisa, Italy

9.00-9.15

OP43 SERUM SELENIUM IS LOW IN NEWLY DIAGNOSED GRAVES`DISEASE AND AUTOIMMUNE HYPOTHYROIDISM. A POPULATION BASED STUDY

Bülow Pedersen I¹, Knudsen N², Carlé A³, Schomburg L⁴, Köhrle J⁴, Jørgensen T⁵, Perrild H², Rasmussen L⁶, Ovesen L⁷, Laurberg P³

¹Aalborg Hospital. Aarhus University Hospital, Dept. of Endocrinology and Medicine, Aalborg, Denmark, ²Bispebjerg Hospital, Copenhagen, Denmark, ³Aalborg Hospital. Aarhus University Hospital, Aalborg, Denmark, ⁴Institute for Experimental Endocrinology, Berlin, Germany, ⁵Research Centre for Prevention and Health, Glostrup, Denmark, ⁶National Food Institute, Copenhagen, Denmark, ⁷Slagelse Hospital, Slagelse, Denmark

9.15-9.30

OP44 HYPERTHYROIDISM, RATHER THAN AUTOIMMUNITY, SEEMS TO DETERMINE QUALITY OF LIFE IN PATIENTS WITH GRAVES´ DISEASE

Watt T^{1,2}, Hegedüs L³, Bonnema SJ³, Groenvold M², Bjorner JB⁴, Rasmussen ÅK¹, Feldt-Rasmussen U¹

¹Copenhagen University Hospital Rigshospitalet, Dpt. of Medical Endocrinology, Copenhagen, Denmark, ²University of Copenhagen, Health Service Research, Copenhagen, Denmark, ³Odense University Hospital, Department of Endocrinology and Metabolism, Odense, Denmark, ⁴National Research Center for the Working Environment, Copenhagen, Denmark

9.30-9.45

OP45 COMPARISON OF EARLY TOTAL THYROIDECTOMY WITH ANTITHYROID TREATMENT IN PATIENTS WITH MODERATE TO SEVERELY ACTIVE GRAVES' ORBITOPATHY, A RANDOMIZED PROSPECTIVE TRIAL

Erdoğan MF¹, Demir Ö¹, Ersoy RÜ², Gül K³, Ünlütürk U¹, Üç ZA⁴, Mete T⁵, Anıl C⁶, Ertek S⁷, Çakır B², Aral Y⁴, Güler S⁵, Gürsoy A⁸, Erdoğan G⁷, Ankara Thyroid Study Group

¹Ankara University Faculty of Medicine, Endocrinology and Metabolic Diseases, Ankara, Turkey, ²Ankara Atatürk Education and Research Hospital, Endocrinology and Metabolic Diseases, Ankara, Turkey, ³Kahramanmaraş Sütçü İmam University Faculty of Medicine, Endocrinology and Metabolic Diseases, Kahramanmaraş, Turkey, ⁴Ankara Education and Research Hospital, Endocrinology and Metabolic Diseases, Ankara, Turkey, ⁵Ankara Numune Education and Research Hospital, Endocrinology and Metabolic Diseases, Ankara, Turkey, ⁶Başkent University Faculty of Medicine, Endocrinology and Metabolic Diseases, Ankara, Turkey, ⁷Ufuk University Faculty of Medicine, Endocrinology and Metabolic Diseases, Ankara, Turkey, ⁸Güven Hospital, Endocrinology and Metabolic Diseases, Ankara, Turkey

9.45-10.00

OP46 IS THE ASSOCIATION BETWEEN OVERT HYPERTHYROIDISM AND MORTALITY CAUSAL? CRITICAL REVIEW AND META-ANALYSIS

Brandt F¹, Green A², Hegedüs L¹, Brix T¹

¹Odense University Hospital, Department of Endocrinology and Metabolism, Odense, Denmark,

²Odense University Hospital, Research Unit of Clinical Epidemiology, University of Southern Denmark and Center for National Clinical Databases, South, Odense, Denmark

8.00-10.00 Minor Hall

Oral presentations 7: Thyroid Cancer (B) (OP47-OP54)

Chair: Georg Brabant (Lübeck, Germany); Beata Kos-Kudla (Katowice, Poland)

8.00-8.15

OP47 THE TARGETED INACTIVATION OF THE TR β GENE INCREASES RET-PTC₃ - INDUCED GROWTH AND NEOPLASTIC TRANSFORMATION OF THE THYROID GLAND

Selmi-Ruby S¹, D'orazio T¹, Borson-Chazot F¹, Rousset B¹

¹Centre de Recherche en Cancérologie de Lyon, UMR Inserm 1052 CNRS 5286, Lyon, France

8.15-8.30

OP48 TRANSCRIPTOME PROFILING OF LASER-MICRODISSECTED PAPILLARY THYROID CANCER CELLS

Oczko-Wojciechowska M¹, Swierniak M¹, Rusinek D¹, Rusin A², Kowal M¹, Kowalska M¹, Tyszkiewicz T¹, Chekan M³, Krajewska J¹, Czarniecka A⁴, Chmielik E³, Jarzab B¹

¹Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Department of Nuclear Medicine and Endocrine Oncology, Gliwice, Poland, ²Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Center for Translational Research and Molecular Biology of Cancer, Gliwice, Poland, ³Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Department of Tumor Pathology, Gliwice, Poland, ⁴Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Oncology Surgery Clinic, Gliwice, Poland

8.30-8.45

OP49 IGF-I PROLIFERATIVE EFFECTS ARE INHIBITED BY TARGETING PKC IN HUMAN MEDULLARY THYROID CARCINOMA CELLS

Molè D¹, Gagliano T¹, Gentilin E¹, Bondanelli M¹, Tagliati F¹, degli Uberti DUC¹, Zatelli MC¹

¹University of Ferrara, Section of Endocrinology, Dept of Biomedical Sciences and Advanced Therapies, Ferrara, Italy

8.45-9.00

OP50 CAMP ANALOGS: A NEW PERSPECTIVE IN THE TREATMENT OF POORLY DIFFERENTIATED THYROID CANCER

Grassi ES¹, de Filippis T², Lucchi S², Calebiro D², Persani L^{1,2,3}

¹University of Milan, Medical Sciences, Milan, Italy, ²IRCCS Istituto Auxologico Italiano, Laboratory of Endocrine-Metabolic Research, Cusano Milanino, Italy, ³IRCCS Istituto Auxologico Italiano, Division of Endocrinology and Metabolic Diseases, Milan, Italy

9.00-9.15

OP51 PODOPLANIN AND PROX 1 IN DIFFERENTIATED THYROID TUMORS

Janik J¹, Strzyżewska-Jówko I¹, Hanusek K¹, Bardadin K², Czerwińska J², Górnicka B³, Kiedrowski M⁴, Olszewski W⁴, Czarnocka B¹

¹Medical Center of Postgraduate Education, Department of Biochemistry and Molecular Biology, Warsaw, Poland, ²Medical Center of Postgraduate Education, Department of Pathology, Warsaw, Poland, ³Medical University of Warsaw, Department of Pathology, Warsaw, Poland, ⁴Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Department of Pathology, Warsaw, Poland

9.15-9.30

OP52 FUNCTIONAL ANALYSIS OF MOLECULAR PROFILE OF CHILDHOOD/ADOLESCENTS RADIATION INDUCED THYROID CANCER

Handkiewicz-Juak D¹, Swierniak M¹, Rusinek D¹, Oczko-Wojciechowska M¹, Dom G², Maenhaut C², Unger K³, Detours V², Bogdanova T⁴, Thomas G³, Kowalska M¹, Chmielik E⁵, Jarzab M⁶, Swierniak A⁷, Jarzab B¹

¹Maria Skłodowska Curie Memorial Cancer Center and Institute of Oncology, Nuclear Medicine and Endocrine Oncology Department, Gliwice, Poland, ²Université Libre de Bruxelles, Institute of Interdisciplinary Research, Bruxelles, Belgium, ³Imperial College London Hammersmith Hospital, Human Cancer Studies Group, Division of Surgery and Cancer, London, United Kingdom, ⁴Institute of Endocrinology and Metabolism, Kiev, Ukraine, ⁵Maria Skłodowska Curie Memorial Cancer Center and Institute of Oncology, Tumor Pathology Department, Gliwice, Poland, ⁶Maria Skłodowska Curie Memorial Cancer Center and Institute of Oncology, Radiation Therapy Department, Gliwice, Poland, ⁷Silesian University of Technology, Gliwice, Poland

9.30-9.45

OP53 RET SOMATIC MUTATIONS ARE NOT AN EARLY EVENT IN THE TUMORAL TRANSFORMATION OF SPORADIC MEDULLARY THYROID CANCER

Romei C¹, Cosci B¹, Ugolini C², Bottici V¹, Molinaro E¹, Agate L¹, Tacito A¹, Basolo F², Miccoli P², Vitti P¹, Pinchera A¹, Elisei R¹

¹University of Pisa, Department of Endocrinology, Pisa, Italy, ²University of Pisa, Department of Surgery, Pisa, Italy

9.45-10.00

OP54 MEK INHIBITION REDUCES THE DEDIFFERENTIATION INDUCED BY EPIDERMAL GROWTH FACTOR, RESTORING THE EXPRESSION OF AND THE IODIDE TRANSPORT MEDIATED BY THE SODIUM IODIDE SYMPORTER (NIS) IN CULTURED THYROCYTES

Ingeson C¹, Carlsson T¹, Nilsson M¹

¹University of Gothenburg, Sahlgrenska Academy, Institute of Biomedicine, Gothenburg, Sweden

10.00-10.30 Coffee Break

10.30-12.00 Minor Hall

Symposium 5 Basic: Thyroid hormone and metabolism

Chair: Ana Aranda (Madrid, Spain); Janusz Nauman (Warsaw, Poland)

Local control of thyroid hormone action and energy homeostasis

Antonio Bianco (Miami, USA)

Control of thermogenesis and lipid metabolism by T3 and its analogs. Induction of uncoupling protein 1 in white fat

Maria Jesus Obregon (Madrid, Spain)

The effects of thyroid hormone on muscle metabolism via regulation of uncoupling protein 3

Maria Moreno (Benevento, Italy)

10.30-12.00 Main Hall (Aula Duza)

Symposium 6 Clinical: Monitoring of thyroid cancer

Chair: Maria Alevizaki (Athens, Greece); Alicja Hubalewska-Dydejczyk (Krakow, Poland)

PET scanning (including FDG, I-124, FDOPA) in thyroid carcinoma

Sophie Leboulleux (Villejuif, France)

Use of sensitive Tg assays in the follow-up of DTC

Rossella Elisei (Pisa, Italy)

Follow-up of MTC including imaging and biochemical markers

Barbara Jarzab (Gliwice, Poland)

12.00-13.00 Poster Exhibition Hall

Lunch and Poster Discussions 3: Poster Sessions PO20-PO28

Posters P212-P309

Thyroid Cancer (clinical) 7: Posters P212-P222 / Chair: Clive Harmer London, UK)

Thyroid Cancer (clinical) 8: Posters P223-P232 / Chair: Nese Colak Ozbey (Istanbul, Turkey)

Thyroid Cancer (basic/translational) 3: Posters P233-P241 / Chair: Christine Spitzweg (Munich, Germany)

Graves' Hyperthyroidism 3: Posters P242-P252 / Chair: Stig Andersson (Aalborg, Denmark)

Thyroid Hormone & Bone: Posters P253-P261 / Chair: Peter Smyth (Dublin, Ireland)

Hypothyroidism 2: Posters P262-P275 / Chair: Agathokles Tsatsoulis (Joannina, Greece)

Goiter/Nodules 2: Posters P276-P289 / Chair: Hans Graf (Merces, Brazil)

Genetics of Thyroid Disease: Posters P290-P297 / Chair: Thomas Brix (Odense, Denmark)

Thyroid Cell Biology and Thyroid Hormone Action: P298-P309 / Chair: Mikael Nilsson (Göteborg, Sweden)

13.00-14.00 **Main Hall (Aula Duza)**

Lunch Symposium Bayer Healthcare

CHALLENGES AND OPPORTUNITIES IN THE TREATMENT OF PATIENTS WITH RAI-REFRACTORY DIFFERENTIATED THYROID CANCER (DTC)

Welcome and Introduction

Alicja Hubalewska-Dydejczyk (Krakow, Poland)

Challenges in Defining RAI-Refractory DTC and Review of the Current Treatment Algorithm

Martin Schlumberger (Paris, France)

Targeted Therapies in RAI-Refractory DTC :Rationale for the Use and clinical development

Marcia Brose (Philadelphia, USA)

Multi-disciplinary perspectives in the Treatment of RAI-Refractory DTC: A Case-Study Approach

Johannes Smit (Leiden, The Netherlands)

Marcia Brose

Alicja Hubalewska-Dydejczyk

Martin Schlumberger

14.00-14.45

Meet the Expert (parallel sessions)

MTE 9 Senate Hall Signalling pathways in the thyroid

Davide Calebiro (Würzburg, Germany)

MTE 10 Lecture Hall Novel treatment modalities for thyroid cancer

Jan Smit (Leiden, The Netherlands)

MTE 11 Minor Hall Thyroid and Pregnancy: results of a survey among ETA members

Kris Poppe (Brussels, Belgium)

14.45-15.00 Coffee Break

15.00-17.00 Main Hall (Aula Duza)

Oral presentations 8: Hypothyroidism, Goiter and Nodules (OP55-OP62)

Chair: Laszlo Hegedus (Odense, Denmark); Jerzy Sowinski (Poznan, Poland)

15.00-15.15

OP55 THYROID HORMONES, ANDROGEN RECEPTORS AND TESTICULAR DEVELOPMENT

Rijntjes E¹, Snaas S², Swarts HJM², Keijer J², Teerds KJ²

¹Charité Universitätsmedizin Berlin, Institute for Experimental Endocrinology, Berlin, Germany,

²Wageningen University, Department of Animal Sciences, Wageningen, Netherlands

15.15-15.30

OP56 MICRORNAS EXPRESSION FOR DIFFERENTIATION OF BENIGN AND MALIGNANT THYROID NODULES STARTING FROM CELLS OF FINE NEEDLE ASPIRATION

Ferrarini E¹, Agretti P¹, Candelieri A², Rago T¹, Conforti D², Musmanno R², Miccoli P¹, Di Coscio G¹, Pinchera A¹, Vitti P¹, Tonacchera M¹

¹Università di Pisa, Pisa, Italy, ²Università della Calabria, Cosenza, Italy

15.30-15.45

OP57 DIAGNOSTIC VALUE OF ULTRASONOGRAPHY TO DISTINGUISH BETWEEN BENIGN AND MALIGNANT THYROID NODULES. A PROSPECTIVE STUDY WITH 13902 PATIENTS

Solymsi T¹

¹Bugat Hospital, Thyroid Outpatient Department, Gyongyos, Hungary

15.45-16.00

OP58 CURRENT PRACTICE TO DIAGNOSE AND TREAT THYROID NODULES IN GERMANY

Bormann R¹, Adler J-B², Scholz M³, Paschke R¹

¹Universität Leipzig, Klinik für Endokrinologie und Nephrologie, Leipzig, Germany, ²Wissenschaftliches Institut der AOK (WIdO), Forschungsbereich Integrierte Analysen, Berlin, Germany, ³Universität Leipzig, Institut für medizinische Informatik, Statistik und Epidemiologie, Leipzig, Germany

16.00-16.15

OP59 INTRODUCTION OF THE DANISH IODINE FORTIFICATION PROGRAM: IMPACT ON DRUG AND TREATMENT COSTS

Cerqueria C¹, Knudsen N², Ovesen L³, Laurberg P⁴, Perrild H², Rasmussen LB⁵, Jørgensen T^{1,6}

¹Research Centre for Prevention and Health, Glostrup, Denmark, ²Bispebjerg Hospital, Department of Endocrinology and Gastroenterology, Copenhagen, Denmark, ³Slagelse Hospital, Department of Gastroenterology, Slagelse, Denmark, ⁴Aalborg Hospital, Aarhus University Hospital, Department of Endocrinology, Aalborg, Denmark, ⁵National Food Institute, Technical University of Denmark, Department of Nutrition, Søborg, Denmark, ⁶University of Copenhagen, Faculty of Health Sciences, Copenhagen, Denmark

16.15-16.30

OP60 IODINE DEFICIENCY DISORDERS IN THE SO-CALLED HIMALAYAN GOITRE BELT: A TWO DECADE PROFILE

Chandola-Saklani A¹, Farswan A¹, Bamola VD¹, Lakhera PC², Kathait A², Kumar D²

¹Apeejay Stya University, Centre for Biosciences and Clinical Research, Gurgaon, India, ²HNB Garhwal Central University, Department of Biotechnology, Srinagar Garhwal, India

16.30-16.45

OP61 LEVOTHYROXINE MONOTHERAPY CANNOT GUARANTEE EUTHYROIDISM IN ALL ATHYREOTIC PATIENTS

Latina A¹, Frasca F¹, Vigneri R¹, Gullo D¹

¹Garibaldi Hospital, University of Catania, Endocrinology Division, Dept. of Clinical and Molecular Biomedicine, Catania, Italy

16.45-17.00

OP62 NEWBORN SEX RATIO IS ASSOCIATED WITH MATERNAL TSH

Miñambres J¹, Ovejero D², García-Patterson A², Adelantado JM², Corcoy R²

¹Hospital de la Santa Creu i Sant Pau, Endocrinology, Barcelona, Spain, ²Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

15.00-17.00 Minor Hall

Oral presentations 9: Thyroid Cell Biology and Genetics (OP63-OP70)

Chair: Paolo Beck-Peccoz (Milano, Italy); AnHELLI Syrenicz (Szczecin, Poland)

15.00.15.15

OP63 TSH COMPENSATES THYROID SPECIFIC IGF1 RECEPTOR KNOCKOUT AND CAUSES PAPILLARY THYROID TUMOURS

Müller K¹, Führer D¹, Mittag J², Klötting N¹, Blüher M¹, Weiss RE³, Many M-C⁴, Schmid KW⁵, Krohn K⁶

¹University of Leipzig, Department of Internal Medicine, Division of Endocrinology, Diabetologia and Nephrology, Leipzig, Germany, ²Karolinska Institute, Department of Cell and Molecular Biology, Stockholm, Sweden, ³The University of Chicago, Department of Medicine, Section of Adult and Pediatric Endocrinology, Diabetes and Metabolism, Chicago, United States, ⁴Universite catholique de Louvain, Medical School, Brussels, Belgium, ⁵University of Duisburg-Essen, Institute of Pathology and Neuropathology, Essen, Germany, ⁶University of Leipzig, IZKF - Core Unit DNA Technologies, Leipzig, Germany

15.15-15.30

OP64 MICRORNAs REGULATE THYROID CELL PROLIFERATION INDUCED BY TSH AND THYROGLOBULIN

Akama T¹, Kawashima A¹, Wu H¹, Tanigawa K¹, Sue M¹, Yoshihara A¹, Ishido Y¹, Suzuki K¹

¹National Institute of Infectious Diseases, Higashimurayama-shi, Japan

15.30-15.45

OP65 EXPRESSION, MATURATION AND TURNOVER STUDIES OF PENDRIN VARIANTS WITH NORMAL OR SLIGHTLY REDUCED FUNCTION

Vezzoli V¹, Cirello V², Bazzini C³, Muzza M², Castorina P⁴, Maffini A⁴, Beck-Peccoz P^{2,4}, Persani L^{1,2}, Meyer G³, Fugazzola L⁴

¹IRCCS Istituto Auxologico Italiano, Research Laboratory of Endocrinology and Metabolic Disorders, Milan, Italy, ²University of Milan, Dept of Medical Sciences, Milan, Italy, ³University of Milan, Laboratory of Molecular and Transport Physiology, Department of Biomolecular Sciences and Biotechnology, Milan, Italy, ⁴Fondazione IRCCS Ca' Granda, Endocrine and Genetic Units, Milan, Italy

15.45-16.00

OP66 A "CUSTOMIZED" CGH-ARRAY THYROARRAY[®] IDENTIFIES GENETIC DEFECTS IN CONGENITAL HYPOTHYROIDISM NOT DETECTABLE BY PCR AND SEQUENCING

Moya CM¹, Vallespín E², Szkudlarek A¹, Persani L³, Martín-Pena M⁴, Fugazzola L⁵, Polak M⁴, Visser T⁶, Lapunzina P², Nevado J², Moreno JC¹

¹INGEMM- Institute for Medical and Molecular Genetics. La Paz University Hospital, Thyroid Molecular Laboratory, Madrid, Spain, ²INGEMM- Institute for Medical and Molecular Genetics. La Paz University Hospital, Structural and Functional Genomics Laboratory, Madrid, Spain, ³IRCCS Istituto Auxologico Italiano, Endocrinology and Metabolic Diseases, Milan, Italy, ⁴Necker-Enfants Malades Hospital, Pediatric Endocrinology, Paris, France, ⁵Fondazione IRCCS Policlinico, Endocrinology and Diabetology Unit, Milan, Italy, ⁶Erasmus Medical Center, Internal Medicine, Rotterdam, Netherlands

16.00-16.15

OP67 FUNCTIONAL CHARACTERIZATION OF TSHR HINGE REGION RESIDUES IDENTIFIED FURTHER TEN TSH INTERACTION SITES OUTSIDE OF THE LRR

Mueller S¹, Szkudlinski MW², Schaarschmidt J¹, Günther R³, Paschke R¹, Jaeschke H¹

¹University of Leipzig, Department of Internal Medicine, Neurology and Dermatology, Leipzig, Germany, ²Trophogen Inc., Rockville, United States, ³University of Leipzig, Institute of Biochemistry, Leipzig, Germany

16.15-16.30

OP68 BIALLELIC DUOX2 VARIANTS APPEAR INVARIABLY ASSOCIATED WITH PERMANENT CONGENITAL HYPOTHYROIDISM

Muzza M¹, Zamproni J², Persani L³, Cortinovis F², Vigone MC², Rabbiosi S², Beccaria L⁴, Visser TJ⁵, Moreno J⁶, Weber G²

¹Fondazione IRCCS Cà Granda, Endocrinology Unit, Milan, Italy, ²San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Department of Pediatrics, Milan, Italy, ³University of Milan, and Istituto Auxologico Italiano, Department of Medical Sciences, Milan, Italy, ⁴A. Manzoni Hospital, Pediatric Unit, Lecco, Italy, ⁵Erasmus Medical Center, Internal Medicine, Rotterdam, Netherlands, ⁶"La Paz" University Hospital, Thyroid Molecular Laboratory-INGEMM- Institute for Medical and Molecular Genetics, Madrid, Spain

16.30-16.45

OP69 SUBCELLULAR LOCALIZATION OF S6K1 AND S6K2 IS RELATED TO FUNCTIONAL ACTIVITY OF RAT THYROCYTES *IN VITRO*

Khoruzhenko A¹, Cherednyk O¹, Tykhonkova I¹, Filonenko V¹

¹Institute of Molecular Biology and Genetics, Department of Cell Signaling, Kyiv, Ukraine

16.45-17.00

OP70 REGULATION OF H₂O₂ GENERATION BY THYROGLOBULIN IN FRTL-5

Yoshihara A¹, Kawashima A¹, Tanigawa K¹, Akama T¹, Wu H¹, Sue M¹, Ishido Y¹, Hiroi N², Yoshino G², Suzuki K¹

¹Laboratory of Molecular Diagnostics, Leprosy Research Center, National Institute of Infectious Diseases, Tokyo, Japan, ²Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan

17.15-18.45 Main Hall (Aula Duza)

General Assembly

20.00

Gala Dinner

Wednesday, 14.9.2011

8.00-10.00 Main Hall (Aula Duza)

Oral presentations 10: Thyroid Cancer clinical (OP71-OP78)

Chair: Laurence Leenhardt (Paris, France); Marek Dedecjus (Lodz, Poland)

8.00-8.15

OP71 TI-RADS SCORE: CLINICAL EFFICIENCY EVALUATED WITH THE BETHESDA SYSTEM IN A ONE-YEAR PROSPECTIVE STUDY ON 2480 NODULES

Russ G¹, Bienvenu-Perrard M¹, Rouxel A¹, Royer B¹, Bigorgne C¹

¹Centre de Pathologie et d'Imagerie, Paris, France

8.15-8.30

OP72 FOSBRETABULIN TROMETHAMINE (CA4P), A TUBULIN-BINDING VASCULAR DISRUPTING AGENT (VDA), IS ASSOCIATED WITH IMPROVED 1-YEAR SURVIVAL IN ANAPLASTIC THYROID CANCER (ATC) PATIENTS TREATED IN 5 INDEPENDENT PROSPECTIVE STUDIES COMPARED TO A LARGE SINGLE INSTITUTION HISTORICAL SERIES

Balkissoon J¹, Langecker P¹, Lu S-P¹, Remick S², Sosa JA³, Elisei R⁴, Mciver B⁵, Bal CS⁶, Gramza A⁷, Jarzab B⁸, Haugen B⁹, Gitlitz B¹⁰, Lu C¹¹, Marur S¹², Licitra L¹³, Ondrey F¹⁴, Karandikar SM¹⁵, Ben-Yosef R¹⁶, Khuri F¹⁷, Koussis H¹⁸

¹Oxigene, Oncology, South San Francisco, United States, ²West Virginia University, Medicine, Morgantown, United States, ³Yale University School of Medicine, Surgery, Division of Endocrine Surgery and Surgical Oncology, New Haven, United States, ⁴University of Pisa, Endocrinology, Pisa, Italy, ⁵Mayo Clinic, Endocrinology, Rochester, United States, ⁶AIIMS, Nuclear Medicine Therapy, New Delhi, India, ⁷National Cancer Institute, Head and Neck Oncology, Bethesda, United States, ⁸MSC Memorial Cancer Centre and Institute of Oncology, Gliwice, Poland, ⁹University of Colorado, Endocrinology, Aurora, United States, ¹⁰USC Norris Cancer Center, Los Angeles, United States, ¹¹MD Anderson Cancer Center, Houston, United States, ¹²Johns Hopkins University, Baltimore, United States, ¹³Istituto dei Tumori, Otolaryngology, Milano, Italy, ¹⁴University of Minnesota, Otolaryngology, Minneapolis, United States, ¹⁵Ruby Hall Clinic, Pune, Maharashtra, India, ¹⁶Tel Aviv Sourasky Medical Center, Head and Neck Oncology, Tel Aviv, Israel, ¹⁷Emory University, Atlanta, United States, ¹⁸Istituto Oncologico Veneto IRCCS, Padova, Italy

8.30-8.45

OP73 MIRNA EXPRESSION PATTERNS DIFFERENTIATE BETWEEN FOLLICULAR THYROID CARCINOMA (FTC) AND FOLLICULAR THYROID ADENOMA (FA)

Stokowy T^{1,2}, Wojtaś B¹, Fujarewicz K², Jarzab M¹, Pfeifer A¹, Jarzab B¹, Krogdahl A³, Hauptmann S⁴, Paschke R⁵, Eszlinger M⁵

¹Cancer Center and Institute of Oncology, Nuclear Medicine and Endocrine Oncology Department, Gliwice, Poland, ²Silesian University of Technology, Systems Engineering Group, Institute of Automatic Control, Gliwice, Poland, ³Odense University Hospital, Department of Pathology, Odense, Denmark, ⁴University of Halle, Institute for Pathology, Halle, Germany, ⁵University of Leipzig, Division of Endocrinology and Nephrology, Leipzig, Germany

8.45-9.00

OP74 COMPARISON OF FOUR STRATEGIES OF RADIOIODINE ABLATION: FINAL RESULTS OF THE RANDOMIZED, PROSPECTIVE ESTIMABL STUDY ON 752 LOW-RISK THYROID CANCER PATIENTS

Catargi B¹, Borget I², Deandris D², Zerdoud S³, Bridji B⁴, Bardet S⁵, Schwartz C⁶, Toubert M⁷, Bonichon F⁸, Benhamou E², Schlumberger M², ESTIMABL Study Group

¹Centre Hospitalier Universitaire, Bordeaux, France, ²Institut Gustave-Roussy, Villejuif, France, ³CLCC, Toulouse, France, ⁴CLCC, Nantes, France, ⁵CLCC, Caen, France, ⁶CLCC, Reims, France, ⁷APHP, Paris, France, ⁸Institut Bergonié, Bordeaux, France

9.00-9.15

OP75 HILO: MULTICENTRE RANDOMISED PHASE III CLINICAL TRIAL OF HIGH VS LOW DOSE RADIOIODINE, WITH OR WITHOUT RECOMBINANT HUMAN THYROID STIMULATING HORMONE (RHTSH), FOR REMNANT ABLATION FOR DIFFERENTIATED THYROID CANCER

Mallick U¹, Harmer C², Clarke S³, Moss L⁴, Nicol A⁵, Clarke P⁶, Smellie J⁷, McCready R⁸, Farnell K⁹, Franklyn J⁶, Nutting C¹⁰, Yap B¹¹, Lemon C¹², Wadley J¹³, Gerrard G¹⁴, Roques T¹⁵, Macias E¹⁶, Whitaker S¹⁷, Abdul-Hamid A¹⁸, Alvarez P¹⁹, Kadalayil L¹⁹, Hackshaw A¹⁹

¹Newcastle Hospitals NHS Trust, Northern Centre for Cancer Treatment, High Heaton, United Kingdom, ²formerly Royal Marsden Hospital, London, United Kingdom, ³Guys & St Thomas's Hospital, London, United Kingdom, ⁴Velindre Hospital, Cardiff, United Kingdom, ⁵Southern General Hospital, Glasgow, United Kingdom, ⁶University of Birmingham, Birmingham, United Kingdom, ⁷Chelsea and Westminster Hospital, London, United Kingdom, ⁸Brighton and Sussex Medical School, Brighton, United Kingdom, ⁹Butterfly Cancer Trust UK, Newcastle, United Kingdom, ¹⁰Royal Marsden Hospital, London, United Kingdom, ¹¹Christie Hospital, Manchester, United Kingdom, ¹²Mount Vernon Hospital, Northwood, United Kingdom, ¹³Weston Park Hospital, Sheffield, United Kingdom, ¹⁴Cookridge Hospital, Leeds, United Kingdom, ¹⁵Norfolk & Norwich Univ Hospital NHS Trust, Norwich, United Kingdom, ¹⁶East Kent NHS Trust and Canterbury Hospital, Kent, United Kingdom, ¹⁷Royal Surrey County Hospital, Guildford, United Kingdom, ¹⁸Hull & East Yorkshire, Princess Royal Hospital, Hull, United Kingdom, ¹⁹University College London, London, United Kingdom

9.15-9.30

OP76 NOT ALL NEW RET MUTATIONS SHOW TRANSFORMING ACTIVITY WHEN ANALYZED BY IN SILICO AND IN VITRO ASSAYS

Elisei R¹, Cosci B¹, Vivaldi A¹, Romei C¹, Gemignani F², Landi S², Tacito A¹, Ciampi R¹, Bottici V¹, Cappagli V¹, Vitti P¹, Pinchera A¹

¹University of Pisa, Department of Endocrinology, Pisa, Italy, ²University of Pisa, Department of Biology, Pisa, Italy

9.30-9.45

OP77 THYROID AUTOIMMUNITY AND THYROID CANCER: PATHOLOGICAL AND MOLECULAR STUDY IN A LONGITUDINAL SERIES OF UNSELECTED NODULES

Boi E¹, Caria P², Borghero A¹, Frau DV², Cappai A¹, Dettori T², Riola A¹, Maurelli I¹, Lai ML³, Calò PG⁴, Nicolosi A⁴, Vanni R², Mariotti S¹

¹University of Cagliari, Department of Medical Sciences 'M. Aresu', Monserrato - Cagliari, Italy,

²University of Cagliari, Department of Biomedical Science and Technology, Monserrato - Cagliari,

Italy, ³University of Cagliari, Department of Cytomorphology, Cagliari, Italy, ⁴University of Cagliari, Department of Surgical and Odontostomatological Sciences, Monserrato - Cagliari, Italy

9.45-10.00

OP78 CLINICAL SIGNIFICANCE OF ANTI-THYROID ANTIBODIES (AT-AB) TITER TREND IN A LONG-TERM FOLLOW-UP OF PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA (DTC)

Lorusso L¹, Agate L¹, Latrofa F¹, Bottici V¹, Molinaro E¹, Viola D¹, Grasso L¹, Pinchera A¹, Vitti P¹, Elisei R¹

¹Department of Endocrinology, University of Pisa, Pisa, Italy

8.00-10.00 Minor Hall

Oral presentations 11: Thyroid Hormone 2 (OP79-OP86)

Chair: Warner Simonides (Amsterdam, The Netherlands); Janusz K. Mysliwiec (Bialystok, Poland)

8.00-8.15

OP79 NOVEL TRANSGENIC TOOLS ILLUMINATE THE COORDINATED DEVELOPMENT OF THE THYROID GLAND AND THE CARDIOVASCULAR SYSTEM IN ZEBRAFISH EMBRYOS

Opitz R¹, Maquet E¹, Horicks F¹, Rodriguez W¹, Costagliola S¹

¹ULB, IRIBHM, Brussels, Belgium

8.15-8.30

OP80 THE THYROID HORMONES INHIBIT TRANSCRIPTIONAL RESPONSES TO THE TRANSFORMING GROWTH FACTOR β

Ruiz-Llorente L¹, Martín-Orozco RM¹, Ardila S¹, Fanjul LF¹, Aranda A¹

¹Inst. Investigaciones Biomedicas (IIB), CSIC-UAM, Madrid, Spain

8.30-8.45

OP81 EFFECTS OF MCT8 AND MCT10 ON THE BIOLOGICAL ACTIVITY OF T3

van Mullem AAA¹, Peeters RP¹, Visser TJ¹

¹Erasmus MC, Internal Medicine, Rotterdam, Netherlands

8.45-9.00

OP82 TYPE 3 DEIODINASE IS HIGHLY EXPRESSED IN PROLIFERATING MYOBLASTS AND DURING THE EARLY PHASE OF MUSCLE REGENERATION

Dentice M¹, Luongo C¹, Ambrosio R¹, Sibilio A¹, Damiano V¹, De Stefano MA¹, Marsili A², Fenzi G¹, Larsen PR², Salvatore D¹

¹Università degli studi di Napoli 'Federico II', Molecular and Clinical Endocrinology and Oncology, Naples, Italy, ²Brigham and Women's Hospital and Harvard Medical School, Thyroid Section, Division of Endocrinology, Diabetes and Hypertension, Boston, United States

9.00-9.15

OP83 TISSUE 3-IODOTHYRONAMINE UPTAKE IN VIVO: COMPARISON WITH EXPRESSION OF TRACE AMINE ASSOCIATED RECEPTORS

Frascarelli S¹, Chiellini G¹, Carnicelli V¹, Ghelardoni S¹, Erba P², Manfredi C², Mariani G², Zucchi R¹

¹University of Pisa, Dip. di Scienze dell'Uomo e dell'Ambiente, Pisa, Italy, ²University of Pisa, Dip. di Oncologia, Pisa, Italy

9.15-9.30

OP84 UPTAKE AND METABOLIC EFFECTS OF 3-IODOTHYRONAMINE IN RAT LIVER

Ghelardoni S¹, Chiellini G¹, Frascarelli S¹, Marchini M¹, Saba A¹, Zucchi R¹

¹University of Pisa, Dip. di Scienze dell'Uomo e dell'Ambiente, Pisa, Italy

9.30-9.45

OP85 THE ROLE OF MICRORNA AND PROMOTER METHYLATION IN REGULATION OF THYROID HORMONE RECEPTOR BETA EXPRESSION IN RENAL CANCER

Wojcicka A¹, Piekietko-Witkowska A¹, Kedzierska H¹, Boguslawska J¹, Nauman A¹

¹The Medical Centre of Postgraduate Education, Department of Biochemistry and Molecular Biology, Warsaw, Poland

9.45-10.00

OP86 DISTURBED ALTERNATIVE SPLICING OF TYPE 2 DEIODINASE IN PITUITARY TUMORS

Piekietko-Witkowska A¹, Kedzierska H¹, Wojcicka A¹, Grajkowska WA^{2,3}, Mandat T⁴, Matyja EM^{2,4}, Bonicki W⁴, Nauman P⁵

¹The Medical Centre of Postgraduate Education, Department of Biochemistry and Molecular Biology, Warsaw, Poland, ²M. Mossakowski Medical Research Centre, Polish Academy of Sciences, Department of Experimental and Clinical Neuropathology, Warsaw, Poland, ³The Children's Memorial Health Institute, Department of Pathology, Warsaw, Poland, ⁴M. Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, Department of Neurosurgery, Warsaw, Poland, ⁵Institut of Psychiatry and Neurology, Department of Neurosurgery, Warsaw, Poland

10.00-10.15 Coffee Break

10.15-11.45 Minor Hall

Symposium 7 Basic: Thyroid hormone disrupters

Chair: Theo Visser (Rotterdam, The Netherlands); Barbara Czarnocka (Warsaw, Poland)

Thyroid hormone signalling in early development: a new window of vulnerability for endocrine disruption

Barbara Demeneix (Paris, France)

Sunburn and thyroid dysfunction: the effect of UV blockers on the thyroid

Josef Köhrle (Berlin, Germany)

Putting out the thyroid with flame retardants: polybrominated compounds

Eddy Rijntjes (Berlin, Germany)

10.15-11.45 Main Hall (Aula Duza)

Symposium 8 Clinical: Perspectives in the therapy of Graves' disease

Chair: George J. Kahaly (Mainz, Germany); Tomasz Bednarczuk (Warsaw, Poland)

Unmet medical needs and therapeutic options in Graves' disease

Luigi Bartalena (Varese, Italy)

Selenium in Graves' hyperthyroidism and orbitopathy

Claudio Marcocci (Pisa, Italy)

The CD-20-positive depleting agent, Rituximab

Laszlo Hegedus (Odense, Denmark)

11.45 Closing Ceremony Main Hall (Aula Duza)

Presentation of the following prizes:

Young Investigators Prize (Clinical/Basic)

sponsored by Thermo Fisher Scientific

ETA Max Koenig Poster Prize (Clinical)

Sponsored by the ETA

ETA Max Koenig Poster Prize (Basic)

Sponsored by the ETA